{{Drugbox
| verifiedrevid = 443878113
| IUPAC_name = 2-butyl-3-({4-[2-(2''H''-1,2,3,4-tetrazol-5-yl)phenyl]phenyl}methyl)-1,3-diazaspiro[4.4]non-1-en-4-one
| image = Irbesartan skeletal.svg

<!--Clinical data-->
| tradename = Avapro
| Drugs.com = {{drugs.com|monograph|irbesartan}}
| MedlinePlus = a698009
| licence_EU = Aprovel
| licence_US = Irbesartan
| pregnancy_category = D <small>([[Australia|Au]])</small>
| legal_status = S4 <small>(Au)</small>, POM <small>([[United Kingdom|UK]])</small>, ℞-only <small>([[U.S.]])</small>
| routes_of_administration = Oral

<!--Pharmacokinetic data-->
| bioavailability = 60–80%
| protein_bound = ~90%
| metabolism = [[Hepatic]] ([[CYP2C9]])
| elimination_half-life = 11–15 hours
| excretion = [[Renal]] 20%, [[feces|faecal]] 65%

<!--Identifiers-->
| CASNo_Ref = {{cascite|correct|CAS}}
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 138402-11-6
| ATC_prefix = C09
| ATC_suffix = CA04
| PubChem = 3749
| IUPHAR_ligand = 589
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
 | DrugBank = DB01029
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 3618
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = J0E2756Z7N
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D00523
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 5959
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 1513

<!--Chemical data-->
 | C=25 | H=28 | N=6 | O=1 
| molecular_weight = 428.53
| smiles = O=C1N(\C(=N/C12CCCC2)CCCC)Cc5ccc(c3ccccc3c4nnnn4)cc5
| InChI = 1/C25H28N6O/c1-2-3-10-22-26-25(15-6-7-16-25)24(32)31(22)17-18-11-13-19(14-12-18)20-8-4-5-9-21(20)23-27-29-30-28-23/h4-5,8-9,11-14H,2-3,6-7,10,15-17H2,1H3,(H,27,28,29,30)
| InChIKey = YOSHYTLCDANDAN-UHFFFAOYAO
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C25H28N6O/c1-2-3-10-22-26-25(15-6-7-16-25)24(32)31(22)17-18-11-13-19(14-12-18)20-8-4-5-9-21(20)23-27-29-30-28-23/h4-5,8-9,11-14H,2-3,6-7,10,15-17H2,1H3,(H,27,28,29,30)
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = YOSHYTLCDANDAN-UHFFFAOYSA-N
}}
'''Irbesartan''' ([[International Nonproprietary Name|INN]]) ({{IPAc-en|icon|ɜr|b|ə|ˈ|s|ɑr|t|ən}}) is an [[angiotensin II receptor antagonist]] used mainly for the treatment of [[hypertension]]. Irbesartan was developed by Sanofi Research (now part of [[sanofi-aventis]]). It is jointly marketed by [[sanofi-aventis]] and [[Bristol-Myers Squibb]] under the [[trade name]]s '''Aprovel''', '''Karvea''', and '''Avapro'''.

==Clinical use==
{{dablink|Main article: [[Angiotensin II receptor antagonist]]}}
===Indications===
As with all angiotensin II receptor antagonists, irbesartan is indicated for the treatment of [[hypertension]]. Irbesartan may also delay progression of diabetic nephropathy and is also indicated for the reduction of renal disease progression in patients with type 2 diabetes,<ref name="Lewis-2001">{{cite journal | author=Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I; Collaborative Study Group. | title=Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes | journal=N Engl J Med | year=2001 | volume=345 | issue=12 | pages=851–60 | pmid=11565517 | doi=10.1056/NEJMoa011303}}</ref> hypertension and microalbuminuria (>30 mg/24 hours) or proteinuria (>900 mg/24 hours).<ref name="Rossi2006">Rossi S, editor. [[Australian Medicines Handbook]] 2006. Adelaide: Australian Medicines Handbook; 2006. ISBN 0-9757919-2-3</ref>

===Combination with diuretic===
Irbesartan is also available in a combination formulation with a low dose [[thiazide diuretic]], invariably [[hydrochlorothiazide]], to achieve an additive antihypertensive effect. Irbesartan/hydrochlorothiazide combination preparations are marketed under similar trade names to irbesartan preparations, including '''Irda''', '''CoIrda''', '''CoAprovel''', '''Karvezide''', '''Avalide''' and '''Avapro HCT'''.

=== Heart failure===
A large randomized trial following 4100+ men and women with heart failure and normal ejection fraction (>=45%) over 4+ years found no improvement in study outcomes or survival with irbesartan as compared to [[placebo]].<ref name="pmid19001508">{{cite journal
| author = Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR, Anderson S, Donovan M, Iverson E, Staiger C, Ptaszynska A
| title = Irbesartan in patients with heart failure and preserved ejection fraction
| journal = N. Engl. J. Med.
| volume = 359
| issue = 23
| pages = 2456–67
| year = 2008
| month = December
| pmid = 19001508
| doi = 10.1056/NEJMoa0805450
| url =  
}}</ref>

==Market==
BMS annual sales approx $1.3bn. Sanofi-aventis annual sales approx $2.1bn. In the United States, a generic version is available. Patent expired March 2012.

==References==
{{reflist}}

==See also==
*[[Angiotensin II receptor antagonist]]

{{Angiotensin II receptor antagonists}}

[[Category:Angiotensin II receptor antagonists]]
[[Category:Sanofi]]
[[Category:Bristol-Myers Squibb]]
[[Category:Tetrazoles]]
[[Category:Biphenyls]]
[[Category:Lactams]]
[[Category:Spiro compounds]]
[[Category:Nitrogen heterocycles]]